Core Insights - Wall Street analysts anticipate Merit Medical (MMSI) will report quarterly earnings of $0.83 per share, reflecting a year-over-year increase of 2.5% [1] - Expected revenues for the quarter are projected at $349.39 million, which represents a 7.7% increase from the same quarter last year [1] - The consensus EPS estimate has been revised upward by 1% in the last 30 days, indicating a reassessment by covering analysts [1] Revenue Projections - Analysts predict 'Revenue- Cardiovascular- Peripheral Intervention' will reach $141.35 million, indicating a 5.4% increase from the prior-year quarter [4] - 'Revenue- Cardiovascular- Cardiac Intervention' is expected to be $93.51 million, reflecting a 3.6% year-over-year change [4] - 'Revenue- Endoscopy' is projected to reach $17.94 million, suggesting a significant increase of 93.1% year over year [4] Additional Revenue Insights - 'Revenue- Cardiovascular- OEM' is estimated at $46.68 million, indicating a 13.3% increase from the previous year [5] - The total 'Revenue- Cardiovascular' is expected to be $331.43 million, reflecting a year-over-year change of 5.1% [5] - 'Revenue- Cardiovascular- Custom Procedural Solutions' is projected to reach $49.87 million, suggesting a modest increase of 0.5% year over year [6] Stock Performance - Shares of Merit Medical have shown a return of -1.4% over the past month, compared to a -0.5% change in the Zacks S&P 500 composite [6] - With a Zacks Rank 2 (Buy), MMSI is expected to outperform the overall market in the near future [6]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Merit Medical (MMSI) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company is a manufacturer of disposable medical devices, which positions it well in the growth stock category [3] Group 2: Earnings Growth - Merit Medical has a historical EPS growth rate of 21.5%, with projected EPS growth of 11.2% for the current year, significantly outperforming the industry average of 6.6% [5] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Merit Medical stands at 12.2%, compared to an industry average of -0.2%, indicating strong cash generation capabilities [6] - The company's annualized cash flow growth rate over the past 3-5 years is 11.5%, while the industry average is only 2.1% [7] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Merit Medical, with the Zacks Consensus Estimate for the current year increasing by 0.5% over the past month [8] Group 5: Investment Potential - Merit Medical has achieved a Growth Score of B and a Zacks Rank 2, suggesting it is a solid choice for growth investors and a potential outperformer [10]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Merit Medical (MMSI) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Merit Medical has a historical EPS growth rate of 21.5%, with projected EPS growth of 11.2% for the current year, surpassing the industry average of 10% [4]. - The company’s strong earnings growth is a key factor attracting investor interest, particularly for growth investors who favor double-digit growth rates [3]. Group 2: Cash Flow Growth - Merit Medical's year-over-year cash flow growth stands at 12.2%, significantly higher than the industry average of -2% [5]. - The historical annualized cash flow growth rate for the company is 11.5% over the past 3-5 years, compared to the industry average of 2% [6]. Group 3: Earnings Estimate Revisions - The current-year earnings estimates for Merit Medical have been revised upward, with the Zacks Consensus Estimate increasing by 0.5% over the past month [8]. - Positive trends in earnings estimate revisions are correlated with near-term stock price movements, indicating strong potential for the company [7]. Group 4: Overall Assessment - Merit Medical has achieved a Growth Score of B and a Zacks Rank of 2, reflecting its strong growth potential and positive earnings estimate revisions, making it a solid choice for growth investors [10].

Core Insights - Merit Medical (MMSI) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 6.02% [1][3] - The company reported earnings of $0.86 per share for the last quarter, surpassing the Zacks Consensus Estimate of $0.80 per share by 7.50% [2] - The positive Earnings ESP of +3.03% indicates that analysts are optimistic about Merit Medical's near-term earnings potential, combined with a Zacks Rank of 2 (Buy) [6] Earnings Performance - In the previous quarter, Merit Medical's earnings were $0.92 per share against an expected $0.88, resulting in a surprise of 4.55% [2] - The favorable change in earnings estimates reflects analysts' growing confidence in the company's performance [3] Earnings ESP and Predictions - The Zacks Earnings ESP is a valuable metric that compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate predictions [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [4] Upcoming Earnings Report - Merit Medical's next earnings report is anticipated to be released on February 25, 2025, and the current indicators suggest a potential earnings beat [6]

Merit Medical's Strategic Acquisitions and Market Position - The acquisition of Cook Medical's lead management portfolio is expected to enhance Merit Medical's position in the cardiac intervention market, particularly in Europe, with an estimated annual addressable opportunity of over $900 million across multiple regions [1] - The addition of the lead management business is anticipated to contribute more than $100 million in combined annualized CRM/EP revenues starting in 2025, strengthening the company's global cardiac intervention market presence [1] - The acquisition is also expected to boost Merit Medical's fast-growing, high-margin cardiac rhythm management/electrophysiology (CRM/EP) business [7] Merit Medical's Financial Performance and Guidance - Preliminary full-year 2024 revenues are estimated to be between $1.355 billion and $1.357 billion, representing a 7.7-7.9% increase from 2023 [4] - At constant currency, full-year 2024 revenues are projected to grow by 8.4-8.6% compared to 2023 [5] - The company plans to issue its full-year 2025 guidance alongside its fourth-quarter 2024 results announcement [6] Merit Medical's U.S. Market Strategy and WRAPSODY Program - The company is focused on entering the U.S. market following premarket approval, with a comprehensive U.S. commercial strategy in development [12] - Positive six-month findings from the WRAPSODY WAVE pivotal trial and progress in U.S. regulatory and reimbursement strategies highlight the potential of the WRAPSODY program [8] Merit Medical's Stock Performance and Industry Comparison - Shares of Merit Medical lost 0.9% between Oct. 1 and Dec. 31, 2024, underperforming the industry's 0.8% rise and the S&P 500's 3.7% gain [2] - Despite the short-term underperformance, the company's Zacks Rank of 2 (Buy) reflects positive sentiment [9] Industry Peers and Their Performance - Cencora (COR) has an estimated long-term growth rate of 10.4% and gained 0.2% between Oct. 1 and Dec. 31, 2024, outperforming the industry's 12.7% decline [3] - Labcorp (LH) has an estimated long-term growth rate of 8.4% and saw its shares rally 4.6% compared to the industry's 0.8% growth during the same period [3][10] - Cardinal Health (CAH) has an estimated long-term growth rate of 10.5% and gained 7.2% compared to the industry's 0.8% growth between Oct. 1 and Dec. 31, 2024 [13]

Core Viewpoint - Merit Medical Systems, Inc. reported preliminary unaudited revenue for the year ended December 31, 2024, in the range of approximately $1.355 to $1.357 billion, indicating a projected increase of about 7.7% to 7.9% compared to the previous year [2][8]. Financial Performance - The preliminary constant currency revenue for the year ended December 31, 2024, increased by approximately 8.4% to 8.6% compared to the prior year [2][8]. - The preliminary unaudited revenue for 2024 is estimated to be between $1.355 billion and $1.357 billion, with a year-over-year increase of 7.7% to 7.9% [8][10]. Upcoming Announcements - Merit plans to announce its financial results for the quarter and year ended December 31, 2024, and provide fiscal year 2025 guidance on February 25, 2025 [3][8]. - An investor conference call is scheduled for the same day at 5:00 p.m. Eastern [3][4]. Non-GAAP Financial Measure - The company uses a non-GAAP financial measure of constant currency revenue to provide insights into underlying business trends and performance, which may be useful for period-over-period comparisons [5][6]. - The constant currency revenue is adjusted for foreign exchange rates and hedging transactions, reflecting a more accurate performance measure [6][10].

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has received FDA premarket approval for its WRAPSODY Cell-Impermeable Endoprosthesis, which is expected to enhance its market position in the vascular intervention space and drive future revenue growth [20][19]. Company Summary - MMSI currently has a market capitalization of $5.72 billion, with fiscal 2024 revenue estimates at $1.35 billion, reflecting a 7.2% growth from fiscal 2023 [2]. - The WRAPSODY device is designed to improve long-term vessel patency in dialysis patients, addressing complications such as stenosis and thrombosis [12][4]. - The WRAPSODY WAVE pivotal trial showed promising results, with primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months [13]. - Following the FDA approval announcement, MMSI's shares increased by 2.03% to $98.22, with a 29.9% gain over the past year compared to the industry’s 2.2% growth [10]. Industry Summary - The global hemodialysis market was valued at $76.9 billion in 2022 and is projected to reach $111.8 billion by 2032, growing at a CAGR of 3.8% [21]. - The need for improved dialysis access solutions is underscored by the prevalence of chronic cardiac diseases and end-stage renal disease, driving demand for advanced medical devices like the WRAPSODY [21][22]. - The FDA approval of the WRAPSODY device positions Merit Medical to capitalize on the growing market for vascular interventions, enhancing its competitive edge and opening new revenue streams [19].

Core Insights - Merit Medical Systems, Inc. has received premarket approval from the US FDA for the WRAPSODY Cell-Impermeable Endoprosthesis, allowing for commercialization in the USA starting in 2025 [6] - The WRAPSODY device is designed to improve long-term vessel patency in hemodialysis patients, addressing common issues such as stenosis and thrombosis [12][19] - Clinical trial results indicate high efficacy of the WRAPSODY device, with primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months [18] Company Overview - Merit Medical, founded in 1987, specializes in the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures [10] - The company employs approximately 7,200 individuals globally and serves hospitals worldwide with a dedicated sales force and clinical support team [10] Product Details - The WRAPSODY device features a unique design with a nitinol stent frame and a multi-layer structure aimed at reducing tissue accumulation and improving blood flow [7][12] - The device is indicated for use in treating stenosis or occlusion in the dialysis access outflow circuit, specifically in peripheral veins of individuals with AV fistulas and at the venous anastomosis of synthetic AV grafts [11] Market Context - In the United States, approximately 687,000 procedures are performed annually to maintain dialysis access, with nearly 100,000 involving stent placement [17] - The WRAPSODY device is expected to set a new standard of care in the treatment of vascular access complications for dialysis patients, as indicated by the positive outcomes from the WAVE trial [19]

SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Me ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Sty ...